Comparative Pharmacology
Head-to-head clinical analysis: CARBOPLATIN versus CYTOXAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBOPLATIN versus CYTOXAN.
CARBOPLATIN vs CYTOXAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carboplatin forms platinum-DNA adducts, causing intrastrand crosslinks and G2/M cell cycle arrest, leading to apoptosis.
Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell cycle nonspecific cytotoxicity. It requires hepatic activation by cytochrome P450 enzymes to form active metabolites, primarily phosphoramide mustard.
IV infusion over 15-60 minutes, target AUC 4-6 using Calvert formula (dose = target AUC × (GFR + 25)). Adults: typical initial dose 400 mg/m² every 4 weeks or AUC 5-6 every 3-4 weeks.
500-1500 mg/m² IV every 2-4 weeks or 1-5 mg/kg/day PO for 10-14 days.
None Documented
None Documented
Terminal elimination half-life: 2.6-5.9 hours in adults with normal renal function. In patients with creatinine clearance <60 mL/min, half-life is prolonged (up to 17-26 hours). Clinically, dosing adjustments are required based on Calvert formula using glomerular filtration rate.
Clinical Note
moderateCarboplatin + Digoxin
"Carboplatin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCarboplatin + Digitoxin
"Carboplatin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCarboplatin + Deslanoside
"Carboplatin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCarboplatin + Acetyldigitoxin
"Carboplatin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life of cyclophosphamide is 3-12 hours (range 2-19 h) in adults; the half-life of active metabolites (e.g., 4-hydroxycyclophosphamide) is approximately 8-10 hours. Half-life is prolonged in hepatic impairment (up to 20 h) and reduced in dose adjustments.
Renal: ~65% of platinum excreted in urine within 24 hours, primarily as unchanged carboplatin; ~32% as metabolites. Biliary/fecal excretion is minimal (<6%).
Renal elimination of unchanged cyclophosphamide (5-30%) and metabolites (primarily 4-ketocyclophosphamide and carboxyphosphamide) accounts for approximately 80% of total clearance; fecal excretion is minimal (<5%).
Category D/X
Category C
Alkylating Agent
Alkylating Agent